Uniqure NV (NASDAQ:QURE) shares rose 6% during mid-day trading on Wednesday . The stock traded as high as $71.16 and last traded at $69.91. Approximately 1,006,839 shares traded hands during trading, an increase of 82% from the average daily volume of 552,958 shares. The stock had previously closed at $65.97.
QURE has been the subject of several research analyst reports. Chardan Capital upped their price target on shares of Uniqure from $70.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Wells Fargo & Co upped their price target on shares of Uniqure from $65.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, March 15th. Cantor Fitzgerald reiterated a “buy” rating and set a $81.00 price target on shares of Uniqure in a report on Thursday, March 7th. Piper Jaffray Companies initiated coverage on shares of Uniqure in a report on Friday, April 12th. They set an “overweight” rating and a $80.00 price target for the company. Finally, BidaskClub upgraded shares of Uniqure from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 13th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $75.82.
The firm has a market cap of $2.64 billion, a price-to-earnings ratio of -29.88 and a beta of 0.95. The company has a quick ratio of 9.51, a current ratio of 9.51 and a debt-to-equity ratio of 0.38.
In related news, insider Christian Klemt sold 1,546 shares of the stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total value of $88,400.28. Following the completion of the sale, the insider now directly owns 54,539 shares in the company, valued at $3,118,540.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 67,376 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $63.96, for a total value of $4,309,368.96. The disclosure for this sale can be found here. Insiders sold 88,922 shares of company stock valued at $5,605,629 over the last 90 days. 2.91% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of QURE. Bank of New York Mellon Corp increased its holdings in shares of Uniqure by 12.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 18,747 shares of the biotechnology company’s stock valued at $682,000 after acquiring an additional 2,129 shares during the last quarter. Vanguard Group Inc. grew its stake in Uniqure by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 101,992 shares of the biotechnology company’s stock worth $3,712,000 after buying an additional 3,992 shares during the last quarter. Vanguard Group Inc grew its stake in Uniqure by 4.1% during the 3rd quarter. Vanguard Group Inc now owns 101,992 shares of the biotechnology company’s stock worth $3,712,000 after buying an additional 3,992 shares during the last quarter. Advisor Group Inc. grew its stake in Uniqure by 5.3% during the 4th quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock worth $288,000 after buying an additional 502 shares during the last quarter. Finally, Northern Trust Corp grew its stake in Uniqure by 2.5% during the 4th quarter. Northern Trust Corp now owns 33,086 shares of the biotechnology company’s stock worth $954,000 after buying an additional 797 shares during the last quarter. Hedge funds and other institutional investors own 60.12% of the company’s stock.
WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4369612/uniqure-nasdaqqure-stock-price-up-6.html.
About Uniqure (NASDAQ:QURE)
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
See Also: Trading Ex-Dividend Strategy
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.